Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $6.7 million.

  • Beam Therapeutics' Other Non-Current Liabilities rose 27.14% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 27.14%. This contributed to the annual value of $5.4 million for FY2024, which is 98.46% up from last year.
  • Latest data reveals that Beam Therapeutics reported Other Non-Current Liabilities of $6.7 million as of Q3 2025, which was up 3.25% from $6.5 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Other Non-Current Liabilities ranged from a high of $37.6 million in Q2 2021 and a low of $1.1 million during Q2 2024.
  • For the 3-year period, Beam Therapeutics' Other Non-Current Liabilities averaged around $5.9 million, with its median value being $5.4 million (2024).
  • Per our database at Business Quant, Beam Therapeutics' Other Non-Current Liabilities skyrocketed by 9,150.99% in 2021 and then tumbled by 89.83% in 2024.
  • Over the past 5 years, Beam Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $31.4 million in 2021, then tumbled by 60.27% to $12.5 million in 2022, then crashed by 78.15% to $2.7 million in 2023, then skyrocketed by 98.46% to $5.4 million in 2024, then climbed by 27.14% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $6.5 million for Q2 2025, and $6.3 million during Q1 2025.